Monographie - Cisplatin

Viimeisin päivitys :
19/11/2024

Cisplatin

Kemiallinen rakenne

Kauppanimi

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Abiplatin	Etelä-Afrikka
Accocit	Meksiko
Briplatin	Japani
Cisplatex	Brasilia
Cisplatin	Australia, Belgia, Itävalta, Kanada, Saudi-Arabia
Cisplatina	Brasilia
Cisplatine	Belgia, Ranska
Cisplatyl	Kreikka, Ranska, Saudi-Arabia, Turkki
Citoplatino	Argentiina, Italia
Citoplax	Brasilia
Corsis	Meksiko
Insel	Brasilia
Neoplatin	Espanja
Pamifect	Intia
Placis	Espanja, Turkki
Platamine	Italia, Kreikka, Marokko, Tunisia
Platanovag	Argentiina
Platiblastin	Itävalta
Platidiam	Puola, Unkari
Platinex	Iso-Britannia, Italia, Saksa
Platinol	Belgia, Hollanti, Itävalta, Kreikka, Luxemburg, Meksiko, Ruotsi, Suomi, Sveitsi, Tanska, Yhdysvallat
Platistil	Espanja
Platistine	Belgia, Brasilia, Luxemburg
Platosin	Belgia, Egypti, Hollanti, Japani, Kreikka, Romania, Turkki, Venezuela
Pronto Platamine	Italia
Zuridry	Meksiko

Viitteet : Cisplatin

	tyyppi	julkaisu
3	Lehti	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
53	Lehti	Henry DW, Marshall JL, Nazzar OD, Fox JL, Leff RD. Stability of cisplatin and ondansetron hydrochloride in admixtures for continuous infusion. Am J Health-Syst Pharm 1995 ; 52: 2570-2573.
57	Lehti	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
81	Lehti	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Lehti	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
85	Lehti	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
91	Lehti	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	Lehti	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
147	Lehti	Pujol Cubells M, Prat Aixela J, Girona Brumos V, Duran Pou S, Villaronga Flaque MV. Stability of cisplatin in sodium chloride 0.9% intravenous solution related to the container’s material. Pharm World Sci 1993 ; 15: 34-36.
149	Lehti	Rochard E, Barthes D, Courtois P. Stability of cisplatin in ethylene vinylacetate portable infusion-pump reservoirs. J Clin Pharm Ther 1992 ; 17: 315-318.
164	Lehti	Benaji B, Dine T, Luyckx M, Brunet C, Goudaliez F, Mallevais ML, Cazin M, Gressier B, Cazin JC. Stability and compatibility of cisplatin and carboplatin with PVC infusion bags. J Clin Pharm Ther 1994 ; 19: 95-100.
169	Lehti	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
244	Lehti	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Lehti	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Lehti	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300	Lehti	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Lehti	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Lehti	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
331	Lehti	Marquardt ED. Visual compatibility of hydroxyzine hydrochloride with various antineoplasic agents. Am J Hosp Pharm 1988 ; 45: 2127.
334	Lehti	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Lehti	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
409	Lehti	Cheung YW, Cradock JC, Vishnuvajjala BR, Flora KP. Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hosp Pharm 1987 ; 44: 124-130.
410	Lehti	Zieske PA, Koberda M, Hines JL, Knight CC, Sriram R, Raghavan NV, Rabinow BE. Characterization of cisplatin degradation as affected by pH and light. Am J Hosp Pharm 1991 ; 48: 1500-1506.
413	Lehti	Stewart CF, Fleming RA. Compatibility of cisplatin and fluorouracil in 0.9% sodium chloride injection. Am J Hosp Pharm 1990 ; 47: 1373-1377.
417	Lehti	Stewart CF, Hampton EM. Stability of cisplatin and etoposide in intravenous admixtures. Am J Hosp Pharm 1989 ; 46: 1400-1404.
492	Lehti	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
660	Lehti	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
742	Lehti	Greene RF, Chatterji DC, Hiranaka PK, Gallelli JF. Stability of cisplatin in aqueous solution. Am J Hosp Pharm 1979 ; 36: 38-43.
855	Lehti	Hrubisko M, Mc Gown AT, Prendiville JA, Radford JA, Thatcher N, Fox BW. Suitability of cisplatin solutions for 14-day continuous infusion by ambulatory pump. Cancer Chemother Pharmacol 1992 ; 29: 252-255.
872	Lehti	Zhang YP, Xu QA, Trissel LA, Gilbert DL, Martinez F. Compatibility and stability of paclitaxel combined with cisplatin and with carboplatin in infusion solutions. Ann Pharmacotherapy 1997 ; 31: 1465-1470.
905	Lehti	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Lehti	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1026	Lehti	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1080	Lehti	La Folette JM, Arbus MH, Lauper RD. Stability of cisplatin admixtures in polyvinyl chloride bags. Am J Hosp Pharm 1985 ; 42: 2652.
1410	Lehti	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Lehti	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Lehti	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Lehti	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1625	Lehti	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1729	Lehti	Mittner A, Vincze Z, Jemnitz K. Stability of cisplatin containing infusion. Pharmazie 1998 ; 53: 490-492.
1925	Lehti	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1950	Lehti	Trissel LA, Yanping Z. Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration. J Oncol Pharm Practice 2004 ; 10: 191-195.
1953	Lehti	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Lehti	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2247	Lehti	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Lehti	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3183	Lehti	Sewell G Physical and chemical stability of cisplatin infusions in PVC containers. EJOP 2010 ; 4, 3: 11-13.
3474	Laboratorio	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3574	Laboratorio	Ondansetron - Résumé des caractéristiques du produit Accord Healthcare France SAS 2013
3578	Laboratorio	Cisplatin - Summary of Product Characteristics Accord Healthcare 2011
3602	Laboratorio	Mesna (Uromitexan®)- Summary of Product Characteristics Baxter SAS 2013
3670	Lehti	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
4084	Laboratorio	Cisplatine - Résumé des caractéristiques du produits Accord Health Care 2017
4137	Lehti	Patel T, Sewell G. Short Report : Extended Stability Studies on Bortezomib Injection and Infusions of Cisplatin and Pemetrexed (all Accord Healthcare). Newsletter Stabilis 2018 41;2-6
4589	Laboratorio	Pemetrexed Mylan - Résumé des caractéristiques du produit Mylan 2021

Mentions Légales